

Itamar Raz

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7280818/publications.pdf>

Version: 2024-02-01

165
papers

19,123
citations

41344

49
h-index

11939

134
g-index

171
all docs

171
docs citations

171
times ranked

15504
citing authors

#	ARTICLE	IF	CITATIONS
1	Protective effects of SGLT-2 inhibitors across the cardiorenal continuum: two faces of the same coin. <i>European Journal of Preventive Cardiology</i> , 2022, 29, 1352-1360.	1.8	26
2	Obesity and effects of dapagliflozin on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus in the DECLARE-TIMI 58 trial. <i>European Heart Journal</i> , 2022, 43, 2958-2967.	2.2	28
3	Myopia and Early-Onset Type 2 Diabetes: A Nationwide Cohort Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, e663-e671.	3.6	3
4	Association of Baseline HbA1c With Cardiovascular and Renal Outcomes: Analyses From DECLARE-TIMI 58. <i>Diabetes Care</i> , 2022, 45, 938-946.	8.6	20
5	Effect of Dapagliflozin on Hematocrit in Patients With Type 2 Diabetes at High Cardiovascular Risk: Observations From DECLARE-TIMI 58. <i>Diabetes Care</i> , 2022, 45, e27-e29.	8.6	10
6	Letter Regarding Normal Albuminuria in Patients With Autopsy-Proven Advanced Diabetic Nephropathy. <i>Kidney International Reports</i> , 2022, 7, 662.	0.8	1
7	Cytochrome c Oxidase Activity as a Metabolic Regulator in Pancreatic Beta-Cells. <i>Cells</i> , 2022, 11, 929.	4.1	7
8	Comment on Oosterwijk et al. High-Normal Protein Intake Is Not Associated With Faster Renal Function Deterioration in Patients With Type 2 Diabetes: A Prospective Analysis in the DIALECT Cohort. <i>Diabetes Care</i> 2022;45:35-41. <i>Diabetes Care</i> , 2022, 45, e67-e68.	8.6	2
9	Sodium-Glucose Cotransporter 2 Inhibitors and Risk of Hyperkalemia in People With Type 2 Diabetes: A Meta-Analysis of Individual Participant Data From Randomized, Controlled Trials. <i>Circulation</i> , 2022, 145, 1460-1470.	1.6	97
10	Efficacy and Safety of Dapagliflozin in Type 2 Diabetes According to Baseline Blood Pressure: Observations From DECLARE-TIMI 58 Trial. <i>Circulation</i> , 2022, 145, 1581-1591.	1.6	13
11	<sc>MMC</sc> celebrating 60 years of experience and expansion. <i>Journal of Diabetes</i> , 2022, , .	1.8	1
12	Obesity in late adolescence and incident type 1 diabetes in young adulthood. <i>Diabetologia</i> , 2022, 65, 1473-1482.	6.3	18
13	Relationship between baseline cardiac biomarkers and cardiovascular death or hospitalization for heart failure with and without sodium-glucose cotransporter 2 inhibitor therapy in <sc>DECLARE-TIMI</sc> 58. <i>European Journal of Heart Failure</i> , 2021, 23, 1026-1036.	7.1	35
14	Haemoglobin A1c is a predictor of COVID-19 severity in patients with diabetes. <i>Diabetes/Metabolism Research and Reviews</i> , 2021, 37, e3398.	4.0	61
15	Adolescent Hypertension and Risk for Early-Onset Type 2 Diabetes: A Nationwide Study of 1.9 Million Israeli Adolescents. <i>Diabetes Care</i> , 2021, 44, e6-e8.	8.6	8
16	<sc>NAFLD</sc> in type 2 diabetes mellitus: Still many challenging questions. <i>Diabetes/Metabolism Research and Reviews</i> , 2021, 37, e3386.	4.0	18
17	Clinical Application of a Novel Genetic Risk Score for Ischemic Stroke in Patients With Cardiometabolic Disease. <i>Circulation</i> , 2021, 143, 470-478.	1.6	32
18	Management of patients with diabetes and obesity in the COVID-19 era: Experiences and learnings from South and East Europe, the Middle East, and Africa. <i>Diabetes Research and Clinical Practice</i> , 2021, 172, 108617.	2.8	31

#	ARTICLE	IF	CITATIONS
19	Adolescent Nonalcoholic Fatty Liver Disease and Type 2 Diabetes in Young Adulthood. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e34-e44.	3.6	13
20	Tackling obesity during the COVID-19 pandemic. Diabetes/Metabolism Research and Reviews, 2021, 37, e3393.	4.0	2
21	Cardiorenal outcomes with dapagliflozin by baseline glucose-lowering agents: Post hoc analyses from <sc>DECLARE-TIMI</sc> 58. Diabetes, Obesity and Metabolism, 2021, 23, 29-38.	4.4	28
22	Stuttering and Incident Type 2 Diabetes: A Population-Based Study of 2.2 Million Adolescents. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e978-e987.	3.6	4
23	Changes in Albuminuria Predict Cardiovascular and Renal Outcomes in Type 2 Diabetes: A Post Hoc Analysis of the LEADER Trial. Diabetes Care, 2021, 44, 1020-1026.	8.6	30
24	The efficacy and safety of dapagliflozin in women and men with type 2 diabetes mellitus. Diabetologia, 2021, 64, 1226-1234.	6.3	15
25	Genetic Risk Score to Identify Risk of Venous Thromboembolism in Patients With Cardiometabolic Disease. Circulation Genomic and Precision Medicine, 2021, 14, e003006.	3.6	6
26	Cardiovascular, Renal, and Metabolic Outcomes of Dapagliflozin Versus Placebo in a Primary Cardiovascular Prevention Cohort: Analyses From DECLARE-TIMI 58. Diabetes Care, 2021, 44, 1159-1167.	8.6	25
27	From glucose lowering agents to disease/diabetes modifying drugs: a "SIMPLE" approach for the treatment of type 2 diabetes. Cardiovascular Diabetology, 2021, 20, 92.	6.8	28
28	Preinfection glycaemic control and disease severity among patients with type <sc>2</sc> diabetes and <sc>COVID-19</sc>: A retrospective, cohort study. Diabetes, Obesity and Metabolism, 2021, 23, 1995-2000.	4.4	9
29	Adolescent Thyroid Disorders and Risk for Type 2 Diabetes in Young Adulthood. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e3426-e3435.	3.6	8
30	Effect of a primary-care-team focused diabetes educational program project on diabetes care quality indicators in a large health maintenance organization. Diabetes Research and Clinical Practice, 2021, 177, 108896.	2.8	4
31	Asthma in Youth and Early-onset Type 2 Diabetes: A Nationwide Study of 1.72 Million Israeli Adolescents. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e5043-e5053.	3.6	2
32	The Effect of Dapagliflozin on Albuminuria in DECLARE-TIMI 58. Diabetes Care, 2021, 44, 1805-1815.	8.6	49
33	Machine learning based study of longitudinal HbA1c trends and their association with all-cause mortality: Analyses from a National Diabetes Registry. Diabetes/Metabolism Research and Reviews, 2021, , e3485.	4.0	5
34	Effect of Dapagliflozin on Cardiovascular Outcomes According to Baseline Kidney Function and Albuminuria Status in Patients With Type 2 Diabetes. JAMA Cardiology, 2021, 6, 801.	6.1	26
35	Serum from type 2 diabetes patients consuming a three-meal diet resets circadian rhythms in cultured hepatocytes. Diabetes Research and Clinical Practice, 2021, 178, 108941.	2.8	1
36	A Biomarker-Based Score for Risk of Hospitalization for Heart Failure in Patients With Diabetes. Diabetes Care, 2021, 44, 2573-2581.	8.6	13

#	ARTICLE	IF	CITATIONS
37	Management of diabetic neuropathy. <i>Metabolism: Clinical and Experimental</i> , 2021, 123, 154867.	3.4	20
38	Adolescent cognitive function and incident early-onset type 2 diabetes. <i>EClinicalMedicine</i> , 2021, 41, 101138.	7.1	4
39	Assessing reproducibility and utility of clustering of patients with type 2 diabetes and established CV disease (SAVOR -TIMI 53 trial). <i>PLoS ONE</i> , 2021, 16, e0259372.	2.5	6
40	Childhood Pancreatitis and Risk for Incident Diabetes in Adulthood. <i>Diabetes Care</i> , 2020, 43, 145-151.	8.6	23
41	SGLT2 inhibitors for primary prevention of cardiovascular events. <i>Journal of Diabetes</i> , 2020, 12, 5-7.	1.8	4
42	Efficacy and Safety of Dapagliflozin in the Elderly: Analysis From the DECLARE-TIMI 58 Study. <i>Diabetes Care</i> , 2020, 43, 468-475.	8.6	72
43	Insulin Therapy: Future Perspectives. <i>American Journal of Therapeutics</i> , 2020, 27, e121-e132.	0.9	28
44	Five years into the Israeli National Diabetes Program – are we on the right track?. <i>Diabetes/Metabolism Research and Reviews</i> , 2020, 37, e3421.	4.0	1
45	Dapagliflozin and Cardiac, Kidney, and Limb Outcomes in Patients With and Without Peripheral Artery Disease in DECLARE-TIMI 58. <i>Circulation</i> , 2020, 142, 734-747.	1.6	44
46	Response by Zelniker et al to Letter Regarding Article, “Effect of Dapagliflozin on Atrial Fibrillation in Patients With Type 2 Diabetes Mellitus: Insights From the DECLARE-TIMI 58 Trial”. <i>Circulation</i> , 2020, 142, e129-e130.	1.6	6
47	Adolescent BMI and early-onset type 2 diabetes among Ethiopian immigrants and their descendants: a nationwide study. <i>Cardiovascular Diabetology</i> , 2020, 19, 168.	6.8	9
48	The relationship between inpatient hyperglycaemia and mortality is modified by baseline glycaemic status. <i>Diabetes/Metabolism Research and Reviews</i> , 2020, 37, e3420.	4.0	4
49	Positioning sulphonylureas in a modern treatment algorithm for patients with type 2 diabetes: Expert opinion from a European consensus panel. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 1705-1713.	4.4	17
50	Cardiovascular and renal outcomes by baseline albuminuria status and renal function: Results from the LEADER randomized trial. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 2077-2088.	4.4	10
51	Digital Diabetes Care System Observations from a Pilot Evaluation Study in Vietnam. <i>International Journal of Environmental Research and Public Health</i> , 2020, 17, 937.	2.6	5
52	Cardiovascular and renal benefits of dapagliflozin in patients with short and long-standing type 2 diabetes: Analysis from the DECLARE-TIMI 58 trial. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 1122-1131.	4.4	16
53	Prediction of progression from pre-diabetes to diabetes: Development and validation of a machine learning model. <i>Diabetes/Metabolism Research and Reviews</i> , 2020, 36, e3252.	4.0	50
54	Effect of Dapagliflozin on Atrial Fibrillation in Patients With Type 2 Diabetes Mellitus. <i>Circulation</i> , 2020, 141, 1227-1234.	1.6	241

#	ARTICLE	IF	CITATIONS
55	Safety of dapagliflozin in a broad population of patients with type 2 diabetes: Analyses from the DECLARE-TIMI 58 study. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 1357-1368.	4.4	26
56	Adolescent Obesity and Early-Onset Type 2 Diabetes. <i>Diabetes Care</i> , 2020, 43, 1487-1495.	8.6	84
57	Safety of Liraglutide in Type 2 Diabetes and Chronic Kidney Disease. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2020, 15, 465-473.	4.5	32
58	Abstract 16139: A Targeted Proteomic Approach to Identify Circulating Biomarkers of Heart Failure Risk in Patients With Type 2 Diabetes Mellitus in DECLARE-TIMI 58. <i>Circulation</i> , 2020, 142, .	1.6	1
59	Abstract 13702: A Novel Genetic Risk Score Predicts Ischemic Stroke in Patients With Cardiometabolic Disease. <i>Circulation</i> , 2020, 142, .	1.6	0
60	Abstract 15701: Relationship Between Cardiac Biomarkers and Major Adverse Cardiovascular Events in DECLARE-TIMI 58. <i>Circulation</i> , 2020, 142, .	1.6	1
61	Metformin Use and Clinical Outcomes Among Patients With Diabetes Mellitus With or Without Heart Failure or Kidney Dysfunction. <i>Circulation</i> , 2019, 140, 1004-1014.	1.6	70
62	Heart Failure Risk Stratification and Efficacy of Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Type 2 Diabetes Mellitus. <i>Circulation</i> , 2019, 140, 1569-1577.	1.6	94
63	SGLT-2 inhibitors for people with type 2 diabetes – Authors' reply. <i>Lancet</i> , 2019, 394, 560-561.	13.7	6
64	Reduction in Glycated Hemoglobin and Daily Insulin Dose Alongside Circadian Clock Upregulation in Patients With Type 2 Diabetes Consuming a Three-Meal Diet: A Randomized Clinical Trial. <i>Diabetes Care</i> , 2019, 42, 2171-2180.	8.6	54
65	Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial. <i>Lancet Diabetes and Endocrinology</i> , 2019, 7, 606-617.	11.4	482
66	Response by Mann et al to Letter Regarding Article, “Effects of Liraglutide Versus Placebo on Cardiovascular Events in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease: Results From the LEADER Trial” <i>Circulation</i> , 2019, 139, e1017-e1018.	1.6	1
67	Effect of Injection Site Cooling and Warming on Insulin Glargine Pharmacokinetics and Pharmacodynamics. <i>Journal of Diabetes Science and Technology</i> , 2019, 13, 1123-1128.	2.2	2
68	Effect of Flash Glucose Monitoring Technology on Glycemic Control and Treatment Satisfaction in Patients With Type 2 Diabetes. <i>Diabetes Care</i> , 2019, 42, 1178-1184.	8.6	120
69	Cardiac and Inflammatory Biomarkers Are Associated with Worsening Renal Outcomes in Patients with Type 2 Diabetes Mellitus: Observations from SAVOR-TIMI 53. <i>Clinical Chemistry</i> , 2019, 65, 781-790.	3.2	8
70	Dapagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Previous Myocardial Infarction. <i>Circulation</i> , 2019, 139, 2516-2527.	1.6	224
71	Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus. <i>Circulation</i> , 2019, 139, 2528-2536.	1.6	415
72	An evaluation of the efficacy and safety of Tofogliflozin for the treatment of type II diabetes. <i>Expert Opinion on Pharmacotherapy</i> , 2019, 20, 781-790.	1.8	4

#	ARTICLE	IF	CITATIONS
73	Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus. <i>Circulation</i> , 2019, 139, 2022-2031.	1.6	523
74	The SONAR study“is there a future for endothelin receptor antagonists in diabetic kidney disease?. <i>Annals of Translational Medicine</i> , 2019, 7, S330-S330.	1.7	5
75	Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2019, 380, 347-357.	27.0	4,159
76	SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. <i>Lancet</i> , The, 2019, 393, 31-39.	13.7	1,958
77	Validity of diagnostic codes and estimation of prevalence of diabetic foot ulcers using a large electronic medical record database. <i>Diabetes/Metabolism Research and Reviews</i> , 2019, 35, e3094.	4.0	7
78	Incidence and Risk Factors for Mortality Following Bariatric Surgery: a Nationwide Registry Study. <i>Obesity Surgery</i> , 2018, 28, 2661-2669.	2.1	25
79	The design and rationale for the Dapagliflozin Effect on Cardiovascular Events (DECLARE)“TIMI 58 Trial. <i>American Heart Journal</i> , 2018, 200, 83-89.	2.7	117
80	Calculating individualized glycaemic targets using an algorithm based on expert worldwide diabetologists: Implications in real-life clinical practice. <i>Diabetes/Metabolism Research and Reviews</i> , 2018, 34, e2976.	4.0	7
81	Cardiovascular Outcomes Trials in Type 2 Diabetes: Where Do We Go From Here? Reflections From a Diabetes Care Editors“Expert Forum. <i>Diabetes Care</i> , 2018, 41, 14-31.	8.6	338
82	DECLARE“TIMI 58: Participants“baseline characteristics. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 1102-1110.	4.4	96
83	The Berlin Declaration: A call to action to improve early actions related to type 2 diabetes. How can specialist care help?. <i>Diabetes Research and Clinical Practice</i> , 2018, 139, 392-399.	2.8	13
84	Digital health technology and diabetes management. <i>Journal of Diabetes</i> , 2018, 10, 10-17.	1.8	74
85	Risk Assessment in Patients With Diabetes With the TIMI Risk Score for Atherothrombotic Disease. <i>Diabetes Care</i> , 2018, 41, 577-585.	8.6	25
86	Patient clusters based on HbA1c trajectories: A step toward individualized medicine in type 2 diabetes. <i>PLoS ONE</i> , 2018, 13, e0207096.	2.5	32
87	Comparison Of Hba1C Goals Proposed By An Algorithm To Those Set By Different Members Of Healthcare Teams Within The Dartmouth Hitchcock Health System. <i>Endocrine Practice</i> , 2018, 24, 705-709.	2.1	2
88	Effects of Liraglutide Versus Placebo on Cardiovascular Events in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease. <i>Circulation</i> , 2018, 138, 2908-2918.	1.6	88
89	Cardiovascular benefit in the limelight: shifting type 2 diabetes treatment paradigm towards early combination therapy in patients with overt cardiovascular disease. <i>Cardiovascular Diabetology</i> , 2018, 17, 117.	6.8	8
90	Glycemic Targets and Prevention of Chronic Complications. <i>Endocrinology</i> , 2018, , 1-31.	0.1	0

#	ARTICLE	IF	CITATIONS
91	The Berlin Declaration: A call to improve early actions related to type 2 diabetes. Why is primary care important?. Primary Care Diabetes, 2018, 12, 383-392.	1.8	10
92	Cardiovascular Outcomes According to Urinary Albumin and Kidney Disease in Patients With Type 2 Diabetes at High Cardiovascular Risk. JAMA Cardiology, 2018, 3, 155.	6.1	78
93	Glycemic Targets and Prevention of Chronic Complications. Endocrinology, 2018, , 421-450.	0.1	0
94	The role of insulin pump therapy for type 2 diabetes mellitus. Diabetes/Metabolism Research and Reviews, 2017, 33, e2822.	4.0	24
95	Pharmacological management of nonalcoholic fatty liver disease in type 2 diabetes. Expert Review of Clinical Pharmacology, 2017, 10, 535-547.	3.1	17
96	Hypoglycaemia manifestations and recurrent events: <sc>Lessons from the <sc>SAVOR-TIMI 53 outcome study. Diabetes, Obesity and Metabolism, 2017, 19, 1045-1050.	4.4	5
97	Response to Comment on Cefalu et al. Update and Next Steps for Real-World Translation of Interventions for Type 2 Diabetes Prevention: Reflections From a <i>Diabetes Care</i> Editorsâ€™ Expert Forum. Diabetes Care 2016;39:1186â€“1201. Diabetes Care, 2017, 40, e23-e24.	8.6	1
98	Health-related quality-of-life implications of cardiovascular events in individuals with type 2 diabetes mellitus: A subanalysis from the Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus (SAVOR)-TIMI 53 trial. Diabetes Research and Clinical Practice, 2017, 130, 24-33.	2.8	22
99	Influences of Breakfast on Clock Gene Expression and Postprandial Glycemia in Healthy Individuals and Individuals With Diabetes: A Randomized Clinical Trial. Diabetes Care, 2017, 40, 1573-1579.	8.6	119
100	Continuous subcutaneous insulin infusionâ€”an opportunity for better care but not a â€œmagic pillâ€•. Endocrine, 2017, 56, 4-6.	2.3	1
101	Effect of Saxagliptin on Renal Outcomes in the SAVOR-TIMI 53 Trial. Diabetes Care, 2017, 40, 69-76.	8.6	205
102	Combined Analysis of Three Large Interventional Trials With Gliptins Indicates Increased Incidence of Acute Pancreatitis in Patients With Type 2 Diabetes. Diabetes Care, 2017, 40, 284-286.	8.6	95
103	Comment on Shahraz et al. Do Patient Characteristics Impact Decisions by Clinicians on Hemoglobin A1c Targets? Diabetes Care 2016;38:e145â€“e146. Diabetes Care, 2016, 39, e227-e227.	8.6	1
104	Predisposing Factors for Any and Major Hypoglycemia With Saxagliptin Versus Placebo and Overall: Analysis From the SAVOR-TIMI 53 Trial. Diabetes Care, 2016, 39, 1329-1337.	8.6	12
105	Outcome studies and safety as guide for decision making in treating patients with type 2 diabetes. Reviews in Endocrine and Metabolic Disorders, 2016, 17, 117-127.	5.7	5
106	Prognostic Implications of Biomarker Assessments in Patients With Type 2 Diabetes at High Cardiovascular Risk. JAMA Cardiology, 2016, 1, 989.	6.1	77
107	Improved Insulin Pharmacokinetics Using a Novel Microneedle Device for Intradermal Delivery in Patients with Type 2 Diabetes. Diabetes Technology and Therapeutics, 2016, 18, 525-531.	4.4	50
108	Proposing a new design for selfâ€•monitoring blood glucose logs. Diabetes/Metabolism Research and Reviews, 2016, 32, 60-62.	4.0	0

#	ARTICLE	IF	CITATIONS
109	Update and Next Steps for Real-World Translation of Interventions for Type 2 Diabetes Prevention: Reflections From a Diabetes Care Editorsâ€™ Expert Forum. Diabetes Care, 2016, 39, 1186-1201.	8.6	113
110	Treatment of Type 2 Diabetes: From â€œGuidelinesâ€ to â€œPosition Statementsâ€ and Back. Diabetes Care, 2016, 39, S146-S153.	8.6	22
111	Introduction to the 5th World Congress on Controversies to Consensus in Diabetes, Obesity and Hypertension (CODHy). Diabetes Care, 2016, 39, S113-S114.	8.6	4
112	Is the Use of DPP-4 Inhibitors Associated With an Increased Risk for Heart Failure? Lessons From EXAMINE, SAVOR-TIMI 53, and TECOS. Diabetes Care, 2016, 39, S210-S218.	8.6	18
113	An update on DPP-4 inhibitors in the management of type 2 diabetes. Expert Opinion on Emerging Drugs, 2016, 21, 409-419.	2.4	52
114	SGLT2 inhibitors and heart failure â€” clinical implications. Nature Reviews Cardiology, 2016, 13, 185-186.	13.7	16
115	Saxagliptin for the treatment of diabetes - a focus on safety. Expert Opinion on Drug Safety, 2016, 15, 697-707.	2.4	7
116	Cardiovascular Outcomes of Patients in SAVOR-TIMI 53 by Baseline Hemoglobin A1c. American Journal of Medicine, 2016, 129, 340.e1-340.e8.	1.5	34
117	Upregulation of Mitochondrial Content in Cytochrome c Oxidase Deficient Fibroblasts. PLoS ONE, 2016, 11, e0165417.	2.5	29
118	Saxagliptin and Cardiovascular Outcomes in Patients With Type 2 Diabetes and Moderate or Severe Renal Impairment: Observations From the SAVOR-TIMI 53 Trial. Diabetes Care, 2015, 38, 696-705.	8.6	141
119	Type 2 diabetes mellitus. Nature Reviews Disease Primers, 2015, 1, 15019.	30.5	1,308
120	Antidiabetic Effect of Interleukin-1Î² Antibody Therapy Through Î²-Cell Protection in the Cohen Diabetes-Sensitive Rat. Diabetes, 2015, 64, 1780-1785.	0.6	13
121	Evaluation of Long-Term Treatment Effect in a Type 1 Diabetes Intervention Trial: Differences After Stimulation With Glucagon or a Mixed Meal. Diabetes Care 2014;37:1384â€“1391. DOI: 10.2337/dc13-1392. Diabetes Care, 2015, 38, 179-179.	8.6	0
122	The addition of E (Empowerment and Economics) to the ABCD algorithm in diabetes care. Journal of Diabetes and Its Complications, 2015, 29, 599-606.	2.3	17
123	Efficacy and Safety of Saxagliptin in Older Participants in the SAVOR-TIMI 53 Trial. Diabetes Care, 2015, 38, 1145-1153.	8.6	73
124	Incidence of Fractures in Patients With Type 2 Diabetes in the SAVOR-TIMI 53 Trial. Diabetes Care, 2015, 38, 2142-2150.	8.6	54
125	Clinical Assessment of Individualized Glycemic Goals in Patients With Type 2 Diabetes: Formulation of an Algorithm Based on a Survey Among Leading Worldwide Diabetologists. Diabetes Care, 2015, 38, 2293-2300.	8.6	42
126	Response to Letter Regarding Article, â€œHeart Failure, Saxagliptin and Diabetes Mellitus: Observations From the SAVOR-TIMI 53 Randomized Trialâ€ Circulation, 2015, 132, e121-2.	1.6	61

#	ARTICLE	IF	CITATIONS
127	Improved Postprandial Glucose Control Using the InsuPad Device in Insulin-Treated Type 2 Diabetes. <i>Journal of Diabetes Science and Technology</i> , 2015, 9, 639-643.	2.2	4
128	Response to Comment on Home et al. Insulin Therapy in People With Type 2 Diabetes: Opportunities and Challenges? <i>Diabetes Care</i> 2014;37:1499-1508. <i>Diabetes Care</i> , 2014, 37, e247-e247.	8.6	1
129	Incidence of Pancreatitis and Pancreatic Cancer in a Randomized Controlled Multicenter Trial (SAVOR-TIMI 53) of the Dipeptidyl Peptidase-4 Inhibitor Saxagliptin. <i>Diabetes Care</i> , 2014, 37, 2435-2441.	8.6	61
130	Improved pharmacokinetic and pharmacodynamic profiles of insulin analogues using InsuPatch, a local heating device. <i>Diabetes/Metabolism Research and Reviews</i> , 2014, 30, 686-692.	4.0	9
131	Beyond Metformin: Safety Considerations in the Decision-Making Process for Selecting a Second Medication for Type 2 Diabetes Management. <i>Diabetes Care</i> , 2014, 37, 2647-2659.	8.6	58
132	Treatment of Recent-Onset Type 1 Diabetic Patients With DiaPep277: Results of a Double-Blind, Placebo-Controlled, Randomized Phase 3 Trial. <i>Diabetes Care</i> , 2014, 37, 1392-1400.	8.6	52
133	Evaluation of Long-Term Treatment Effect in a Type 1 Diabetes Intervention Trial: Differences After Stimulation With Glucagon or a Mixed Meal. <i>Diabetes Care</i> , 2014, 37, 1384-1391.	8.6	15
134	Heart Failure, Saxagliptin, and Diabetes Mellitus: Observations from the SAVOR-TIMI 53 Randomized Trial. <i>Circulation</i> , 2014, 130, 1579-1588.	1.6	594
135	Insulin Therapy in People With Type 2 Diabetes: Opportunities and Challenges?. <i>Diabetes Care</i> , 2014, 37, 1499-1508.	8.6	122
136	Guideline Approach to Therapy in Patients With Newly Diagnosed Type 2 Diabetes. <i>Diabetes Care</i> , 2013, 36, S139-S144.	8.6	57
137	Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus. <i>New England Journal of Medicine</i> , 2013, 369, 1317-1326.	27.0	3,017
138	Personalized Management of Hyperglycemia in Type 2 Diabetes: Reflections from a Diabetes Care Editors' Expert Forum. <i>Diabetes Care</i> , 2013, 36, 1779-1788.	8.6	130
139	Emerging gliptins for type 2 diabetes. <i>Expert Opinion on Emerging Drugs</i> , 2013, 18, 245-258.	2.4	30
140	Dietary copper supplementation restores β -cell function of Cohen diabetic rats: a link between mitochondrial function and glucose-stimulated insulin secretion. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2013, 304, E1023-E1034.	3.5	23
141	Early Insulinization to Prevent Diabetes Progression. <i>Diabetes Care</i> , 2013, 36, S190-S197.	8.6	24
142	Efficacy and Safety of Taspoglutide Monotherapy in Drug-Naive Type 2 Diabetic Patients After 24 Weeks of Treatment. <i>Diabetes Care</i> , 2012, 35, 485-487.	8.6	33
143	Rational therapy for diabetes: early recognition of adverse effects and avoidance of disruptive false alarms. <i>Diabetes/Metabolism Research and Reviews</i> , 2012, 28, 321-324.	4.0	12
144	Post Hoc Subgroup Analysis of the HEART2D Trial Demonstrates Lower Cardiovascular Risk in Older Patients Targeting Postprandial Versus Fasting/Premeal Glycemia. <i>Diabetes Care</i> , 2011, 34, 1511-1513.	8.6	72

#	ARTICLE	IF	CITATIONS
145	The design and rationale of the Saxagliptin Assessment of Vascular Outcomes Recorded in patients with diabetes mellitusâ€“Thrombolysis in Myocardial Infarction (SAVOR-TIMI) 53 Study. <i>American Heart Journal</i> , 2011, 162, 818-825.e6.	2.7	98
146	Impact of the U.S. Food and Drug Administration Cardiovascular Assessment Requirements on the Development of Novel Antidiabetes Drugs. <i>Diabetes Care</i> , 2011, 34, S101-S106.	8.6	69
147	The Continuing Need for Drug Development and Clinical Trials in Type 2 Diabetes and its Complications: Introduction to The RDS Special Issue. <i>Review of Diabetic Studies</i> , 2011, 8, 288-292.	1.3	1
148	The A1C and ABCD of glycaemia management in type 2 diabetes: a physician's personalized approach. <i>Diabetes/Metabolism Research and Reviews</i> , 2010, 26, 239-244.	4.0	104
149	Introduction to the Second World Congress on Controversies to Consensus in Diabetes, Obesity and Hypertension (CODHy): Dilemmas in clinical practice. <i>Diabetes Care</i> , 2009, 32, S149-S150.	8.6	2
150	Effect of a local heating device on insulin and glucose pharmacokinetic profiles in an open-label, randomized, two-period, one-way crossover study in patients with type 1 diabetes using continuous subcutaneous insulin infusion. <i>Clinical Therapeutics</i> , 2009, 31, 980-987.	2.5	51
151	Challenges in developing endpoints for type 1 diabetes intervention studies. <i>Diabetes/Metabolism Research and Reviews</i> , 2009, 25, 694-704.	4.0	19
152	Managing labor and delivery of the diabetic mother. <i>Expert Review of Obstetrics and Gynecology</i> , 2009, 4, 547-554.	0.4	3
153	Effects of Prandial Versus Fasting Glycemia on Cardiovascular Outcomes in Type 2 Diabetes: The HEART2D trial. <i>Diabetes Care</i> , 2009, 32, 381-386.	8.6	320
154	Efficacy and safety of sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes. <i>Current Medical Research and Opinion</i> , 2008, 24, 537-550.	1.9	228
155	DiaPep277(R) Preserves Endogenous Insulin Production by Immunomodulation in Type 1 Diabetes. <i>Annals of the New York Academy of Sciences</i> , 2006, 1079, 340-344.	3.8	22
156	Immune modulation for prevention of type 1 diabetes mellitus. <i>Trends in Biotechnology</i> , 2005, 23, 128-134.	9.3	42
157	Diabetes: insulin resistance and derangements in lipid metabolism. Cure through intervention in fat transport and storage. <i>Diabetes/Metabolism Research and Reviews</i> , 2005, 21, 3-14.	4.0	160
158	Efficacy and safety of biphasic insulin aspart 30 combined with pioglitazone in type 2 diabetes poorly controlled on glibenclamide (glyburide) monotherapy or combination therapy: An 18-week, randomized, open-label study. <i>Clinical Therapeutics</i> , 2005, 27, 1432-1443.	2.5	31
159	Addition of biphasic insulin aspart 30 to rosiglitazone in type 2 diabetes mellitus that is poorly controlled with glibenclamide monotherapy. <i>Clinical Therapeutics</i> , 2003, 25, 3109-3123.	2.5	22
160	Î²-cell function in new-onset type 1 diabetes and immunomodulation with a heat-shock protein peptide (DiaPep277): a randomised, double-blind, phase II trial. <i>Lancet, The</i> , 2001, 358, 1749-1753.	13.7	501
161	Rapid activation of glycogen synthase and protein phosphatase in human skeletal muscle after isometric contraction requires an intact circulation. <i>Pflugers Archiv European Journal of Physiology</i> , 1995, 431, 259-265.	2.8	14
162	Effects of human diabetic serum on the in vitro development of early somite rat embryos. <i>Teratology</i> , 1989, 39, 85-92.	1.6	23

#	ARTICLE	IF	CITATIONS
163	Pharmacokinetic analysis of sustained-release dosage forms of theophylline in humans: Comparison of single and multiple dose studies. <i>Biopharmaceutics and Drug Disposition</i> , 1987, 8, 427-435.	1.9	7
164	Pharmacokinetics of valproic acid in volunteers after a single dose study. <i>Biopharmaceutics and Drug Disposition</i> , 1985, 6, 33-42.	1.9	16
165	Insulin Therapy and Hypoglycemia - Present and Future. , 0, , .		0